EXETER, N.H.--(BUSINESS WIRE)--Bentley Pharmaceuticals, Inc. (NYSE: BNT) (“Bentley” or the “Company”) announced today that its stockholders have approved the Agreement and Plan of Merger, dated as of March 31, 2008, by and among the Company, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) (“Teva”) and Beryllium Merger Corporation (the “Merger Agreement”) and the acquisition of Bentley by Teva was completed. Pursuant to the terms of the Merger Agreement, Bentley became a wholly owned subsidiary of Teva, ceased to be publicly traded and accordingly its common stock will no longer be listed on the New York Stock Exchange. Each outstanding share of the Company’s common stock was converted into the right to receive a portion of the aggregate merger consideration, or approximately $14.82 per share. The aggregate merger consideration paid by Teva was approximately $359.7 million.
